Navigation Links
Jefferson Department of Surgery announces new pancreas tumor registry
Date:10/29/2008

PHILADELPHIA Charles J. Yeo, M.D., Samuel D. Gross Professor and Chair, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, announces the establishment of the new Jefferson Pancreas Tumor Registry (JPTR).

"The purpose of the registry is to further study whether pancreatic cancer occurs more frequently in families with a history of the disease," said Dr. Yeo, who is the principal investigator of JPTR. "It will also be used to determine the environmental and occupational risk factors to which pancreatic cancer patients have been exposed."

The JPTR modeled after the National Familial Pancreas Tumor Registry is a longitudinal study in which participants may engage in long-term follow-up and receive information regarding scientific and epidemiological breakthroughs in pancreatic cancer.

Participants are asked to complete a detailed questionnaire and may be asked to submit a blood sample and/or cheek swab. The questionnaires are designed to elicit the family health history of a patient with pancreatic cancer or a non-affected family member, and to document exposure to occupational and environmental factors, such as residential radon, asbestos and second-hand tobacco smoke.

Research has shown that certain rare genetic conditions are associated with an increased risk of pancreatic cancer, including familial breast-ovarian cancer, familial melanoma, familial colon cancer, hereditary pancreatitis and Peutz-Jegher's syndrome (a rare hereditary condition that results in gastrointestinal polyps). "While we have not identified a causative gene yet to allow predictive testing for pancreatic cancer, we can offer risk assessments and surveillance via imaging, blood tests and endoscopic ultrasound for patients with a strong family history of pancreatic cancer," added Dr. Yeo.

Such high risk patients may be referred to a Jefferson gastroenterologist to discuss the pros and cons of invasive surveillance. The goal is to diagnose pancreatic cancer earlier, when more treatment options are available. For persons who do develop pancreatic cancer, Jefferson physicians may use the results of genetic testing to select the most effective therapy. Targeted therapy for pancreatic cancer is becoming a reality, in part due to recent discoveries made in the laboratory of Jonathan Brody, Ph.D., assistant professor, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, where molecular studies have clearly indicated survival advantages with the use of targeted chemotherapy.


'/>"/>

Contact: Ed Federico
ed.federico@jefferson.edu
Thomas Jefferson University
Source:Eurekalert

Related biology news :

1. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
2. Jefferson receives $11.6M NIH grant to study novel mechanisms of heart failure
3. Jefferson scientists studying the effects of high-dose vitamin C on non-Hodgkin lymphoma patients
4. Jefferson urologists studying regenerated neo-bladder to help spinal cord injury patients
5. Story tips from the Department of Energys Oak Ridge National Laboratory, September 2008
6. Story tips from the US Department of Energys Oak Ridge National Laboratory, August 2008
7. Second Life a first for UH department of health and human performance
8. Story tips from the Department of Energys Oak Ridge National Laboratory, July 2008
9. US Department of Energy Joint Genome Institute announces new genome sequencing projects
10. Story tips from the Department of Energys Oak Ridge National Laboratory, June 2008
11. Story tips from the Department of Energys Oak Ridge National Laboratory, April 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2015.  ... 2015 was $6.9 million, an increase of 61% compared to $4.3 ... fourth quarter of 2015 was $2.6 million compared to $0.2 million ... --> Higher revenue and operating income in the ...
(Date:2/3/2016)... 4, 2016 --> --> ... M (105.0), up 1,187% compared with fourth quarter of 2014. ... 517.6 M (loss: 30.0). Earnings per share increased to SEK ... 537.4 M (neg: 74.7). , --> ... to SEK 2,900.5 M (233.6), up 1,142% compared with 2014. ...
(Date:2/2/2016)... This BCC Research report provides a ... the recent advances in high throughput ‘omic platforms ... forward. Includes forecast through 2019. Use ... opportunities that exist in the bioinformatic market. Analyze ... well as IT and bioinformatics service providers. Analyze ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... Inc. (NASDAQ: NBIX ) today announced its financial results for ... --> --> For the fourth quarter of ... $0.34 loss per share, compared to a net loss of $19.4 ... 2014. For the year ended December 31, 2015, the Company reported ... as compared to a net loss of $60.5 million, or $0.81 ...
(Date:2/11/2016)... International, a not-for-profit organization focused on the ethics and governance ... to patients around the world, today announced that the editors ... the Good Pharma Scorecard an ,Editors, Pick, ... of BMJ Open ,s ,Most Popular Articles, which includes ... read. Ed Sucksmith , assistant editor of ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... information focused on the development and manufacture of biopharmaceuticals and therapeutics, announces ... of the 2016 BioProcess International Awards – Recognizing Excellence in the People, ...
(Date:2/11/2016)... --  BioInformant announces the February 2016 release of ... Tools, and Technologies – Market Size, Segments, Trends, and ... The first and only market research ... has more than a decade of historical information on ... cell type. This powerful 175 page global strategic report ...
Breaking Biology Technology: